当前位置: 首页 >> 检索结果
4081. Cost-effectiveness of catheter ablation in patients with ventricular tachycardia.
作者: H Calkins.;J T Bigger.;S J Ackerman.;S B Duff.;D Wilber.;R A Kerr.;M Bar-Din.;K M Beusterien.;M J Strauss.
来源: Circulation. 2000年101卷3期280-8页
This study evaluated the cost-effectiveness of catheter ablation therapy versus amiodarone for treating ventricular tachycardia (VT) in patients with structural heart disease. The analysis used a societal perspective for a hypothetical cohort of VT patients with implantable cardioverter-defibrillators, who were experiencing frequent shocks.
4082. Infections, inflammation, and the risk of coronary heart disease.
作者: M Roivainen.;M Viik-Kajander.;T Palosuo.;P Toivanen.;M Leinonen.;P Saikku.;L Tenkanen.;V Manninen.;T Hovi.;M Mänttäri.
来源: Circulation. 2000年101卷3期252-7页
The role of infections and inflammation in the pathophysiology of coronary heart disease is emerging. We studied the independent and joint effects of these 2 components on coronary risk.
4083. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial.
作者: J A de Lemos.;E M Antman.;C M Gibson.;C H McCabe.;R P Giugliano.;S A Murphy.;S A Coulter.;K Anderson.;J Scherer.;M J Frey.;R Van Der Wieken.;F Van De Werf.;E Braunwald.
来源: Circulation. 2000年101卷3期239-43页
In the presence of ST-elevation myocardial infarction, patients with successful epicardial reperfusion (TIMI 3 flow) but persistent ST elevation on a 12-lead ECG are at high risk for subsequent death and left ventricular dysfunction. In the TIMI 14 trial, a dose-ranging angiographic study, combined therapy with abciximab plus reduced-dose tPA enhanced the speed and efficacy of epicardial reperfusion. We determined whether the combination of abciximab plus reduced-dose tPA provided additional benefit in terms of myocardial reperfusion, as evidenced by greater resolution of ST elevation.
4084. Endothelium-derived nitric oxide contributes to the regulation of venous tone in humans.
作者: D J Blackman.;J A Morris-Thurgood.;J J Atherton.;G R Ellis.;R A Anderson.;J R Cockcroft.;M P Frenneaux.
来源: Circulation. 2000年101卷2期165-70页
Although nitric oxide (NO) is known to play an important part in the regulation of arterial tone, little is known about its role in veins. The aim of this study was to investigate the role of basal and stimulated NO activity in the regulation of tone of the human venous capacitance bed.
4085. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators.
The potential merits and disadvantages of the use of ionic or nonionic contrast media in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) have been the subjects of controversy. The present study was designed to evaluate the possible influence of both types of contrast media on major adverse cardiac events (MACE) in patients undergoing PTCA.
4086. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.
作者: C M Gibson.;C P Cannon.;S A Murphy.;K A Ryan.;R Mesley.;S J Marble.;C H McCabe.;F Van De Werf.;E Braunwald.
来源: Circulation. 2000年101卷2期125-30页
Although improved epicardial blood flow (as assessed with either TIMI flow grades or TIMI frame count) has been related to reduced mortality after administration of thrombolytic drugs, the relationship of myocardial perfusion (as assessed on the coronary arteriogram) to mortality has not been examined.
4087. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect.
作者: R C Hendel.;T D Henry.;K Rocha-Singh.;J M Isner.;D J Kereiakes.;F J Giordano.;M Simons.;R O Bonow.
来源: Circulation. 2000年101卷2期118-21页
Animal models of therapeutic angiogenesis have stimulated development of clinical application in patients with limited options for coronary revascularization. The impact of recombinant human vascular endothelial growth factor (rhVEGF) on myocardial perfusion in humans has not been reported.
4090. Usefulness of unipolar electrograms to detect isthmus block after radiofrequency ablation of typical atrial flutter.
作者: J Villacastin.;J Almendral.;A Arenal.;N P Castellano.;S Gonzalez.;M Ortiz.;J García.;B Vallbona.;J Moreno.;J F Portales.;E G Torrecilla.
来源: Circulation. 2000年102卷25期3080-5页
RS morphology of the unipolar electrogram is associated with propagation of the wave front through the exploring electrode, whereas positive uniphasic (R) unipolar electrograms are characteristic of the end of activation.
4091. Sympathetic activation by sildenafil.
作者: B G Phillips.;M Kato.;C A Pesek.;M Winnicki.;K Narkiewicz.;D Davison.;V K Somers.
来源: Circulation. 2000年102卷25期3068-73页
Sildenafil citrate is an effective and widely prescribed therapy for erectile dysfunction. Little is known about the effects of sildenafil on neural control of the circulation or about the effects of sildenafil on neurocirculatory stress responses.
4092. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block.
作者: G S Nelson.;R D Berger.;B J Fetics.;M Talbot.;J C Spinelli.;J M Hare.;D A Kass.
来源: Circulation. 2000年102卷25期3053-9页
Left ventricular or biventricular pacing/stimulation can acutely improve systolic function in patients with dilated cardiomyopathy (DCM) and intraventricular conduction delay by resynchronizing contraction. Most heart failure therapies directly enhancing systolic function do so while concomitantly increasing myocardial oxygen consumption (MVO(2)). We hypothesized that pacing/stimulation, in contrast, incurs systolic benefits without raising energy demand.
4093. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators.
作者: P Théroux.;B R Chaitman.;N Danchin.;L Erhardt.;T Meinertz.;J S Schroeder.;G Tognoni.;H D White.;J T Willerson.;A Jessel.
来源: Circulation. 2000年102卷25期3032-8页
The transmembrane sodium/hydrogen exchanger maintains myocardial cell pH integrity during myocardial ischemia but paradoxically may precipitate cell necrosis. The development of cariporide, a potent and specific inhibitor of the exchanger, prompted this investigation of the potential of the drug to prevent myocardial cell necrosis.
4094. Emergency polytetrafluoroethylene-covered stent implantation to treat coronary ruptures.
作者: C Briguori.;T Nishida.;A Anzuini.;C Di Mario.;E Grube.;A Colombo.
来源: Circulation. 2000年102卷25期3028-31页
Coronary perforation is a life-threatening complication of percutaneous interventions. In the past few years, the implantation of covered stents has emerged as a strategy for treatment when the traditional conservative approach (ie, prolonged balloon inflation and reversal of anticoagulation) fails.
4095. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group.
作者: J Y Liu.;N J Birkmeyer.;J H Sanders.;J R Morton.;H F Henriques.;S J Lahey.;R W Dow.;C Maloney.;A W DiScipio.;R Clough.;B J Leavitt.;G T O'Connor.
来源: Circulation. 2000年102卷24期2973-7页
Although dialysis patients are undergoing CABG with increasing frequency, large studies specifically comparing patient characteristics and procedure-related risks in this population have not been performed.
4096. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era?
作者: M H Rubenstein.;L C Harrell.;B V Sheynberg.;H Schunkert.;H Bazari.;I F Palacios.
来源: Circulation. 2000年102卷24期2966-72页
Patients with end-stage renal disease undergoing conventional balloon angioplasty have reduced procedural success and increased complication rates. This study was designed to determine the immediate and long-term outcomes of patients with varying degrees of renal failure undergoing percutaneous coronary intervention in the current device era.
4097. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators.
作者: S P Marso.;D L Bhatt.;M T Roe.;P L Houghtaling.;M Labinaz.;N S Kleiman.;C Dyke.;M L Simmoons.;R M Califf.;R A Harrington.;E J Topol.
来源: Circulation. 2000年102卷24期2952-8页
Patients with a recent episode of non-ST-segment elevation acute coronary syndrome before CABG have higher rates of operative morbidity and mortality than patients with stable coronary syndromes. The efficacy of administering eptifibatide to these patients undergoing in-hospital CABG is unknown.
4098. Randomized comparison of elective stent implantation and coronary balloon angioplasty guided by online quantitative angiography and intracoronary Doppler. DESTINI Study Group (Doppler Endpoint STenting INternational Investigation).
作者: C Di Mario.;J W Moses.;T J Anderson.;R Bonan.;T Muramatsu.;A C Jain.;J Suarez de Lezo.;S Y Cho.;M Kern.;I T Meredith.;D Cohen.;I Moussa.;A Colombo.
来源: Circulation. 2000年102卷24期2938-44页
The purpose of this study was to compare long-term outcomes of coronary stenting in all lesions (elective stenting) or only in lesions with inadequate morphological and functional results after balloon angioplasty (guided PTCA).
4099. Randomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group.
作者: P W Serruys.;B de Bruyne.;S Carlier.;J E Sousa.;J Piek.;T Muramatsu.;C Vrints.;P Probst.;R Seabra-Gomes.;I Simpson.;V Voudris.;O Gurné.;N Pijls.;J Belardi.;G A van Es.;E Boersma.;M A Morel.;B van Hout.
来源: Circulation. 2000年102卷24期2930-7页
Coronary stenting improves outcomes compared with balloon angioplasty, but it is costly and may have other disadvantages. Limiting stent use to patients with a suboptimal result after angioplasty (provisional angioplasty) may be as effective and less expensive.
4100. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
作者: A M Lincoff.;D B Mark.;J E Tcheng.;R M Califf.;M V Bala.;K M Anderson.;L Davidson-Ray.;J D Knight.;C F Cabot.;E J Topol.
来源: Circulation. 2000年102卷24期2923-9页
In the EPILOG trial (Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade), abciximab administered with weight-adjusted heparin diminished the risk of ischemic complications within 30 days by 56% among patients undergoing percutaneous coronary revascularization, without increased bleeding complications.
|